肿瘤临床试验非劣效设计趋向宽松 margin 与更高事件率
该系统评价纳入 291 项已发表的非劣效 III 期肿瘤试验及方案,比较得出非劣效结论与未得出非劣效结论的试验在设计参数上的分布。多变量 logistic 回归显示,得出非劣效结论的几率与更宽松的非劣效 margin 及更高的假设事件率显著相关,提示可能存在偏倚性设计。
要点
- 非劣效 margin 越宽松,得出非劣效结论的几率越高。
- 假设事件率越高,得出非劣效结论的几率越高。
- 建议预注册并透明报告非劣效设计的详细参数。
核心结论
- 研究表明肿瘤临床试验中可能存在扭曲的非劣效设计,导致过多的非劣效结论。
研究设计与样本
- 系统检索 MEDLINE、Embase 和 CENTRAL 数据库至 2020 年 4 月 17 日,纳入非劣效 III 期肿瘤试验及方案共 291 项。
- 采用多变量 logistic 回归比较得出与未得出非劣效结论的试验在基本特征和研究设计参数上的分布。
局限性
- 研究为探索性性质,存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify potential bias in non-inferiority design of published cancer trials, and to provide suggestions for future practice. STUDY DESIGN AND SETTING: We systematically searched MEDLINE, Embase and CENTRAL databases (until April 17, 2020) to obtain non-inferiority phase III cancer trials and protocols. Distribution of essential characteristics and study design parameters was compared between trials with and without concluding non-inferiority using multivariable logistic regression. RESULTS: A total of 291 eligible trials were included. We observed that increased odds of concluding non-inferiority was significantly associated with more lenient non-inferiority margins (OR = 1•94, 95% CI 1•02-3•69) and higher hypothesized event rate (OR = 1•24, 95% CI 1•06-1•47). Trials that established non-inferiority adopted margins that were more dispersedly distributed (dispersion OR = 2•90, 95% CI 1•88-4.48). CONCLUSION: Although limited by the exploratory nature, our study demonstrated existence of possible distorted non-inferiority design which could incur excess non-inferiority in cancer clinical trials. Pre-registration and transparent reporting of detailed non-inferiority design is imperative for future research.
引用
- He Y, Shu C, Li T, et al. Non-inferiority in cancer clinical trials was associated with more lenient margins and higher hypothesized outcome event rates. J Clin Epidemiol. 2021. PMID: 34437946. doi:10.1016/j.jclinepi.2021.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。